The members of the 25x-NBOH series are generally slightly less potent and have a shorter duration than their NBOMe counterparts. Anecdotal evidence suggests minor differences in the physical and subjective effects between the two series.
For example, members of the 25x-NBOH are reportedly more favorable than their NBOMe counterpart in terms of their appreciable body-load. This may be due to the possibility that they are less well absorbed, as they otherwise have similar binding affinities.
The series has little or no history of human use prior to 2012 when NBOMe analogs became available for purchase from online research chemical vendors.
List of 25x-NBOH compounds
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Tolerance and addiction potential
Members of the 25x-NBOH series are not not habit-forming and the desire to use them can actually decrease with use. They are thought to be mostly self-regulating.
Tolerance to the effects of 25x-NBOH is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back at baseline (in the absence of further consumption). 25x-NBOH presents cross-tolerance with all psychedelics, meaning that after the consumption of 25I-NBOMe all psychedelics will have a reduced effect.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
Serotonin syndrome risk
- MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.
- Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
- SSRIs - Such as citalopram and sertraline
- SNRIs - Such as tramadol and venlafaxine
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- United Kingdom - The majority of synthesised 25x-NBOH substances are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause. Any compounds not covered by the clause are illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., Abdollahi, M. (June 2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi: . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.
- The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014
- Psychoactive Substances Act 2016